Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 163

Sort by

Sort Order Select

Journal Articles

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

Sophia Adamia, PhD, Shruti Bhatt, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Catherine A Nicholas, Marissa S Pioso, Ivane Abiatari, MD, Anthony G. Letai, MD PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142596

Published: 2020

Journal Articles

ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application

Subodh Kumar, PhD, Srikanth Talluri, PhD, Jiangning Zhao, PhD MD, Chengcheng Liao, PhD MD, Lakshmi B. Potluri, MBBS, Leutz Buon, Shidai Mu, Jialan Shi, MDPhD, Mychell Neptune-Buon, Chandraditya Chakraborty, PhD, Yu-Tzu Tai, PhD, Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Rao Prabhala, Masood A. Shammas, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 51.

https://doi.org/10.1182/blood-2020-142793

Published: 2020

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136824

Published: 2020

Journal Articles

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Su Wang, PhD, Daisuke Ogiya, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth Wen, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139778

Published: 2020

Journal Articles

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Anil Aktas-Samur, PhD, Abdul Hamid Bazarbachi, MD, Yu-Tzu Tai, PhD, Timothy B. Campbell, MD PhD, Fabio Petrocca, MD, Kristen Hege, MD, Shari Kaiser, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-139040

Published: 2020

Journal Articles

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Cirino Botta, MDPhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Stefano Malvestiti, MD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Paul G. Richardson, MD, Ruben D. Carrasco, MD PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140356

Published: 2020

Journal Articles

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 1809.

https://doi.org/10.1182/blood-2019-123141

Published: 2019

Journal Articles

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Liang Lin, PhD, Lijie Xing, MD, Shih-Feng Cho, MD PhD, Kenneth Wen, Phillip A Hsieh, Metin Kurtoglu, MD PhD, Yi Zhang, C Andrew Stewart, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1811.

https://doi.org/10.1182/blood-2019-121595

Published: 2019

Journal Articles

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Lijie Xing, MD, Liang Lin, PhD, Tengteng Yu, MD PhD, Yuyin Li, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1817.

https://doi.org/10.1182/blood-2019-127163

Published: 2019

Journal Articles

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Lijie Xing, MD, Yuyin Li, PhD, Liang Lin, PhD, Tengteng Yu, MD PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3096.

https://doi.org/10.1182/blood-2019-127135

Published: 2019

Journal Articles

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Gang An, MD, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3105.

https://doi.org/10.1182/blood-2019-130927

Published: 2019

Journal Articles

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Giada Bianchi, MD, Peter G. Czarnecki, MD, Matthew Ho, PhD, Aldo M. Roccaro, MD PhD, Antonio Sacco, RN, Yawara Kawano, MD PhD, Anil Aktas Samur, PhD, Annamaria Gulla, MD, Tianzeng Chen, Kenneth Wen, Xinchen Wu, Yu-Tzu Tai, PhD, Gulden Camci-Unal, PhD, Irene M. Ghobrial, MD, Ruben D. Carrasco, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 507.

https://doi.org/10.1182/blood-2019-128778

Published: 2019

Journal Articles

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Nikhil C. Munshi, MD, Joachim Wahl, PhD, Katja Matthes, Kenneth C. Anderson, MD, Tara Chapman-Arvedson, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 135.

https://doi.org/10.1182/blood-2019-128528

Published: 2019

Journal Articles

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Caroline Ribeiro, PhD, Leon Wert-Lamas, PhD, Annamaria Gulla, MD, Anil Aktas Samur, PhD, Cinzia Federico, PhD, Francesca Scionti, PhD, Yao Yao, PhD, Nicola Amodio, PhD, Giada Bianchi, MD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Carl D. Novina, MD PhD, Massimo Loda, MD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 317.

https://doi.org/10.1182/blood-2019-130730

Published: 2019

Journal Articles

Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Dharminder Chauhan, PhD, Ruben D. Carrasco, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 134.

https://doi.org/10.1182/blood-2019-127845

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Chengwen Li, Shuhua Yi, MD, Mu Hao, Dehui Zou, MD, Fenghuang Zhan, MD PhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4343.

https://doi.org/10.1182/blood-2019-129739

Published: 2019

Journal Articles

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Yuting Yan, Yan Xu, Xuehan Mao, MD, Jiahui Liu, Huishou Fan, Qi Wang, Chenxing Du, Li Zengjun, Shuhua Yi, MD, Rui Lv, Shuhui Deng, MD, Weiwei Sui, Mu Hao, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Gang An, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4405.

https://doi.org/10.1182/blood-2019-124096

Published: 2019

NARROW

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only